Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Mon, 10.06.2024
Evotec SE
Most agenda items adopted with great majority
Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka
Hamburg, Germany, 10 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced [ … ]
Thu, 30.05.2024
Evotec SE
Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity
Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics
Lille University Hospital will provide human biological samp [ … ]
Thu, 30.05.2024
Evotec SE
Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity
Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics
Lille University Hospital will provide human biological samp [ … ]
Tue, 28.05.2024
Evotec SE
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington’s disease
One of Evotec’s largest strategic drug discovery alliances
Hamburg, Germany, 28 May 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20 [ … ]
Tue, 28.05.2024
Evotec SE
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington’s disease
One of Evotec’s largest strategic drug discovery alliances
Hamburg, Germany, 28 May 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20 [ … ]
Wed, 22.05.2024
Evotec SE
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER
STRONG START WITH JUST – EVOTEC BIOLOGICS IN Q1 2024
POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEAR
RESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEG [ … ]
Wed, 15.05.2024
Evotec SE
Hamburg, Germany, 15 May 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call [ … ]
Tue, 30.04.2024
Evotec SE
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES
STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS
JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY
Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based l [ … ]
Wed, 24.04.2024
Evotec SE
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE
PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M
EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST – EVOTEC BIOLOGICS” STARTING Q1 2024
Hamburg, Germany, 24 April 202 [ … ]
Tue, 23.04.2024
Evotec SE
Hamburg, Germany, 23 April 2024:
The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that bega [ … ]